Tehran University Medical Journal

Background: Retinal vein occlusions are one of the most common form of retinal vascular disorders and could lead to vision loss due to macular edema, macular ischemia and sequelae from neovascularization. Anti-venous endothelial growth factor (anti-VEGF) treatment is the choice strategy of treatment for patients with macular edema secondary to central retinal vein occlusion (CRVO). There is an evidence of body with the controversies regarding increment of choroidal thickness in CRVO condition. The current study was designed to determine whether baseline subfoveal choroidal thickness may be an indicator for visual and anatomical outcome of bevacizumab in patients with CRVO macular edema.
Methods: This study was a prospective clinical cohort study that enrolled in 23 new cases of treatment-naïve central retinal vein occlusion (CRVO) from February to July 2017 who were visited in Feiz Eye Hospital, Isfahan, Iran. Patients received a single injection of bevacizumab and were followed for 30 days. Ratio of subfoveal choroidal thickness (SFCT) was measured using enhanced depth imaging spectral-domain optical coherence tomography (EDI-OCT). Ratio of SFCT of the CRVO eye to the fellow healthy eye (SFCT1/F) was taken as independent variable. Changes of best-corrected visual acuity (BCVA) in LogMAR (ΔBCVA, functional response) and secondary to baseline central macular thickness ratio (CMT2/1, anatomical response) in the CRVO eyes were taken for comparative and correlative analytics.
Results: A total of 46 eyes from 23 patients with the mean age of 64.60±10.19 years were included in this study. Baseline SFCT was higher in CRVO eyes (251.91±46.09 µm) in comparison to the fellow eye (206.95±26.62, P<0.0001). Also central macular thickness in CRVO eyes were significantly higher in CRVO eyes in comparison with fellow eye (531.04±38.22 vs 303.30±33.59, respectively, P<0.05). SFCT1/F, correlated moderately with anatomical (CMT2/1) and strongly with functional response (ΔBCVA).
Conclusion: Bilateral evaluation of SFCT by EDI-OCT in all newly diagnosed CRVO cases is recommended to determine if there is a relative increase in choroidal thickness. This may help predict short-term response to anti-VEGF therapy.

Raman spectroscopy, as an emerging and promising molecular assessment tool, has attracted the attention of researchers, especially for disease diagnosis in human organs such as the breast. Although most of the Raman studies on the breast have dealt with ex-vivo examination of either intact or processed excised tissue specimens, there are some in-vivo studies, including intraoperative tumor margin assessment and a few non-invasive studies. Since the non-invasive or minimally invasive Raman assessment technique is an essential need for translation to clinical approaches, in the present article, the most recent and relevant studies in this regard have been reviewed to find and introduce the most proper Raman spectroscopy system’s specifications for in-vivo assessment of breast tissue.
Scholarly documents, including articles, books, and dissertations related to Raman assessment of breast tissue or in-vivo Raman assessment of other human organs, were perused in search of the most relevant technical details of Raman systems employed so far. On the one hand, the present study has covered Raman instrumentation aspects of diverse types of Raman spectroscopy, different types of laser source and their specifications, optical elements used in the delivery and collection of light to and from the tissue such as lenses and fibers, detectors and even calibration settings. On the other hand, the main Raman features corresponding to different breast pathologies have been studied, speculating their variations in a non-invasive setting. Having studied all, we tried to find the best feasible configuration for a Raman system in terms of the ability to meet the needs of a non-invasive, in vivo clinical examination of the breast. 
In terms of the Raman spectroscopy modality and laser source, SORS/TRS and 785nm laser diode, were selected for in vivo examination of the breast respectively. The pertinent parameters of the spectrograph, detector, and fiber optic probe were introduced as well.
In the present study, detailed specifications of a non-invasive, in vivo Raman apparatus for examination of breast tissue have been studied and specified.